Free Trial

Solid Biosciences (SLDB) Projected to Post Quarterly Earnings on Tuesday

Solid Biosciences logo with Medical background

Key Points

  • Solid Biosciences is set to release its Q2 2025 earnings before the market opens on August 12th, with analysts projecting a loss of ($0.51) per share for the quarter.
  • Previously, the company reported a loss of ($0.59) per share for the last quarter, missing estimates by ($0.06).
  • A significant portion of Solid Biosciences' stock, approximately 81.46%, is owned by institutional investors, indicating strong institutional confidence in the company's potential.
  • Looking to export and analyze Solid Biosciences data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). On average, analysts expect Solid Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Solid Biosciences Stock Up 1.6%

SLDB stock traded up $0.10 during trading on Friday, hitting $6.29. The company had a trading volume of 1,125,772 shares, compared to its average volume of 1,445,641. The firm has a 50-day moving average price of $5.40 and a 200-day moving average price of $4.33. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $10.37. The stock has a market cap of $487.54 million, a price-to-earnings ratio of -2.10 and a beta of 2.44.

Institutional Investors Weigh In On Solid Biosciences

Several large investors have recently bought and sold shares of the company. Woodline Partners LP bought a new stake in Solid Biosciences in the first quarter valued at approximately $2,338,000. Goldman Sachs Group Inc. lifted its holdings in shares of Solid Biosciences by 32.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company's stock valued at $667,000 after purchasing an additional 43,910 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Solid Biosciences during the 1st quarter valued at about $418,000. Finally, Creative Planning bought a new position in shares of Solid Biosciences during the 2nd quarter valued at about $57,000. Institutional investors own 81.46% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on SLDB shares. Citigroup started coverage on shares of Solid Biosciences in a research report on Thursday, June 26th. They issued a "buy" rating and a $14.00 price objective for the company. JMP Securities restated a "market outperform" rating and issued a $15.00 price objective on shares of Solid Biosciences in a research report on Friday, June 6th. Wedbush dropped their price objective on shares of Solid Biosciences from $18.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. Chardan Capital cut their price objective on shares of Solid Biosciences from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Finally, Cantor Fitzgerald set a $16.00 price objective on shares of Solid Biosciences and gave the company an "overweight" rating in a report on Monday, July 21st. Ten investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Solid Biosciences presently has a consensus rating of "Buy" and a consensus price target of $15.10.

View Our Latest Analysis on Solid Biosciences

About Solid Biosciences

(Get Free Report)

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

Further Reading

Earnings History for Solid Biosciences (NASDAQ:SLDB)

Should You Invest $1,000 in Solid Biosciences Right Now?

Before you consider Solid Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.

While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid
NVIDIA Earnings: All Signs Point to More Growth Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines